Company Nektar Therapeutics

Equities

NKTR

US6402681083

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.9342 USD +5.55% Intraday chart for Nektar Therapeutics +4.11% +65.35%

Business Summary

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body’s innate and adaptive immunity. Its Rezpegaldesleukin pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. Rezpegaldesleukin is being developed as a self-administered injection.

Number of employees: 137

Sales per Business

USD in Million2022Weight2023Weight Delta
Novel Drug Candidates
100.0 %
92 100.0 % 90 100.0 % -2.10%

Sales per region

USD in Million2022Weight2023Weight Delta
Rest of World
87.3 %
82 89.3 % 79 87.3 % -4.35%
United States
12.7 %
10 10.7 % 11 12.7 % +16.66%

Managers

Managers TitleAgeSince
Chief Executive Officer 71 06-12-31
Chairman 66 91-11-30
Director of Finance/CFO 58 23-04-16
Chief Tech/Sci/R&D Officer 49 15-06-30
Chief Tech/Sci/R&D Officer 58 14-12-31
Investor Relations Contact - 18-10-31
Human Resources Officer - 00-12-31
General Counsel 52 02-04-30
Corporate Officer/Principal - 03-12-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 65 09-12-31
Director/Board Member 70 00-07-31
Chairman 66 91-11-30
Chief Executive Officer 71 06-12-31
Director/Board Member 61 17-09-20
Director/Board Member 67 19-12-15
Director/Board Member 53 21-11-10

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 183,617,817 181,755,961 ( 98.99 %) 0 98.99 %

Shareholders

NameEquities%Valuation
Deep Track Capital LP
9.645 %
18,400,000 9.645 % 13 M $
Deep Track Capital LP
9.645 %
18,400,000 9.645 % 13 M $
Vanguard Global Advisers LLC
6.313 %
12,042,873 6.313 % 9 M $
Acadian Asset Management LLC
4.099 %
7,818,804 4.099 % 6 M $
PRIMECAP Management Co.
3.670 %
7,001,747 3.670 % 5 M $
BlackRock Advisors LLC
3.198 %
6,100,969 3.198 % 4 M $
Monaco Asset Management SAM
3.131 %
5,973,387 3.131 % 4 M $
Citadel Advisors LLC (13f Subfiler)
2.949 %
5,625,000 2.949 % 4 M $
Renaissance Technologies LLC
2.792 %
5,325,475 2.792 % 4 M $
GSA Capital Partners LLP
2.755 %
5,255,790 2.755 % 4 M $

Company contact information

Nektar Therapeutics

455 Mission Bay Boulevard South

94158, San Francisco

+415 482 5300

http://www.nektar.com
address Nektar Therapeutics(NKTR)

Group companies

NameCategory and Sector
Biotechnology

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
0.9342 USD
Average target price
1 USD
Spread / Average Target
+7.04%
Consensus